- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01934309
Clinical Decision-support Reminders to Improve IPT Initiation Among HIV Positive Adults in Western Kenya (TBTech)
March 23, 2023 updated by: Paul Biondich, Indiana University
Does Providing Medical Personnel in the AMPATH Network With Patient-specific Reminders Regarding TB That Are Generated From a Patient's EMR Improve the Prevalence of IPT Initiation and Decrease the Time From Screening to Treatment?
The overall research objective is to evaluate the impact of implementing a reminder system for medical providers to improve TB case-finding and isoniazid preventative therapy (IPT) for adults living with HIV in western Kenya
Study Overview
Detailed Description
The purpose of this study is to evaluate the impact of implementing a clinical decision support reminder system for medical providers (i.e., nurses, clinical officers, medical officers, consultants) to improve tuberculosis case-finding and the use of isoniazid preventative therapy for adults living with HIV in western Kenya.
Study Type
Interventional
Enrollment (Actual)
3782
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Eldoret, Kenya
- AMPATH
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Clusters:
Inclusion Criteria
- active
- uses HIV initial and return encounter paper forms
- enters data into the AMPATH medical records system (AMRS) or sends forms to central location for data entry
- prints or receives printed paper summary sheets with reminders
- interprets chest x-rays
- interprets sputum smear results
- prescribes IPT and dispenses INH
- completed an average of 10 initial adult HIV positive encounters per month in 2012
- HIV Care Clinic
Exclusion Criteria -
Patients:
Inclusion Criteria
- HIV positive
- complete an adult initial encounter at an HIV Care Clinic during the enrollment period
- attend at least one additional appointment within 90 days after the initial encounter
Exclusion Criteria
- history of TB or IPT
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: TB reminders
Receive existing reminders plus new patient-specific reminders about TB screening, prevention, and treatment
|
The intervention to be studied involves providing clinic-based medical care providers (e.g., nurses, clinical officers, medical officers, consultants) with patient-specific clinical reminders regarding TB that are generated from a patient's electronic medical record and based on accepted clinical algorithms for TB screening and treatment.
|
|
No Intervention: No TB reminders
Only receive existing reminders; no TB reminders
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Prescription of Isoniazid
Time Frame: within 3 months of initial encounter
|
Provider prescribes INH within 3 months of patient's initial encounter.
|
within 3 months of initial encounter
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time to isoniazid prophylactic therapy (IPT) initiation
Time Frame: within 3 months of initial encounter
|
The time in weeks from a patient's initial encounter to the week the patient picks up the initial batch of INH from the pharmacy.
|
within 3 months of initial encounter
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Initiation of isoniazid prophylactic therapy (IPT)
Time Frame: within 3 months of initial encounter
|
IPT will be considered "initiated" when a patient picks up the initial batch of the prescribed medications within 3 months of the initial encounter.
|
within 3 months of initial encounter
|
|
Isoniazid prophylactic therapy (IPT) completion
Time Frame: 9 months after treatment initiation
|
Patient completes 9-month course of IPT
|
9 months after treatment initiation
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Lameck O Diero, MBChB, MMed, Moi University College of Health Sciences
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2013
Primary Completion (Actual)
August 1, 2014
Study Completion (Actual)
August 1, 2014
Study Registration Dates
First Submitted
August 29, 2013
First Submitted That Met QC Criteria
September 3, 2013
First Posted (Estimate)
September 4, 2013
Study Record Updates
Last Update Posted (Actual)
March 27, 2023
Last Update Submitted That Met QC Criteria
March 23, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AID-OAA-TO-11-00060
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tuberculosis
-
Global Alliance for TB Drug DevelopmentCompletedTuberculosis | Tuberculosis, Pulmonary | Pulmonary Disease | Multi Drug Resistant Tuberculosis | Drug Sensitive Tuberculosis | Drug-resistant Tuberculosis | Mycobacterium Tuberculosis InfectionUnited States
-
Global Alliance for TB Drug DevelopmentCompletedTuberculosis | Tuberculosis, Pulmonary | Pulmonary Disease | Multi Drug Resistant Tuberculosis | Drug Sensitive Tuberculosis | Drug-resistant Tuberculosis | Mycobacterium Tuberculosis InfectionUnited States
-
Beijing Chest HospitalHuashan Hospital; National Medical Center for Infectious DiseasesNot yet recruitingTuberculosis | Drug-resistant Tuberculosis | Pulmonary Tuberculosis | Rifampicin Resistant TuberculosisChina
-
University of Cape TownUniversity of Stellenbosch; University of Cape Town Lung Institute; University... and other collaboratorsCompletedTuberculosis | Multidrug Resistant Tuberculosis | Extensively-drug Resistant TuberculosisSouth Africa
-
Huashan HospitalThe Hong Kong Polytechnic UniversityNot yet recruitingPulmonary Tuberculosis | Tuberculosis (TB) | Tuberculosis ActiveChina
-
Universiteit AntwerpenAurum Institute; University of Stellenbosch; University of the Free State; Free...RecruitingDrug-resistant Tuberculosis | Rifampicin Resistant Tuberculosis | Pulmonary Tuberculoses | Multidrug Resistant TuberculosisSouth Africa
-
Aarhus University HospitalBandim Health ProjectNot yet recruitingPregnancy | Maternal Health | Tuberculosis (TB) | Tuberculosis Diagnosis | Tuberculosis Infection, LatentGuinea-Bissau
-
Assistance Publique - Hôpitaux de ParisCompletedExtrapulmonary Tuberculosis | Lymph Node Tuberculosis | Bone TuberculosisFrance
-
Centers for Disease Control and PreventionBoston University; Pfizer; Columbia University; University of Texas; University of... and other collaboratorsCompletedMulti-Drug Resistant Tuberculosis | Extensively Drug Resistant TuberculosisSouth Africa
-
Wits Health Consortium (Pty) LtdUniversity of Cape Town; Perinatal HIV Research Unit of the University of the... and other collaboratorsCompletedTuberculosis | Multi Drug Resistant Tuberculosis | Rifampicin Resistant Tuberculosis | Extensively Drug-Resistant Tuberculosis | Pre-XDR-TBSouth Africa
Clinical Trials on TB reminders
-
Mbarara University of Science and TechnologyMassachusetts General Hospital; National Institutes of Health (NIH)Unknown
-
Peking University First HospitalRecruiting
-
SKEZIInstitut National de Recherche pour l'Agriculture, l'Alimentation et l'EnvironnementCompletedGeneral Population (no Specific Condition or Disease)France
-
Peter MacCallum Cancer Centre, AustraliaRecruitingProstate Cancer | Metastatic Castration-resistant Prostate CancerAustralia
-
Indiana UniversityUnited States Agency for International Development (USAID); Moi Teaching and...Unknown
-
Institute for Clinical Effectiveness and Health...University of WashingtonActive, not recruitingTuberculosis | Treatment AdherenceArgentina
-
Societe Francaise de RhumatologieAssistance Publique - Hôpitaux de Paris; University Hospital, ToulouseCompletedRheumatoid ArthritisFrance
-
Assistance Publique - Hôpitaux de ParisCompletedHIV | Tuberculosis | Latent Tuberculosis InfectionFrance
-
National Taiwan University HospitalUnknown
-
Therasid BioscienceCompletedHealthy VolunteersKorea, Republic of